Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AstraZeneca finally reaches vaccine shipping milestone to EU that was due in January

Mon, 10th May 2021 16:37

By Francesco Guarascio

BRUSSELS, May 10 (Reuters) - AstraZeneca Plc has
delivered 50 million doses of its COVID-19 vaccine to European
Union countries, according to EU's latest supply data, a
milestone it was originally due to hit in January.

Repeated cuts to supplies, which contributed to delays in
the EU's vaccination drive, pushed the European executive
commission to sue the Anglo-Swedish drugmaker in late April in a
bid to get more doses by mid-year.

AstraZeneca had shipped nearly 50 million doses as of May 7,
an EU official told Reuters on Monday, citing the latest EU
internal figures on vaccine supplies.

In mid-March, the company had pledged to deliver 50.2
million doses to the EU by the end of April, an AstraZeneca
document seen by Reuters shows.

But AstraZeneca had shipped only 47.6 million doses by the
evening of April 30, a spokesman for the company said, adding
that other doses were sent over the first weekend of May and in
the following days "following requests to not ship to a few
countries that had public holidays during this period".

Immediately after the EU sued the company, AstraZeneca
issued a statement on April 26 saying it would deliver "almost
50 million doses to European countries by the end of April".

Under its contract with the EU, the company had committed to
its "best reasonable efforts" to deliver 300 million doses by
the end of June, of which 70 million were supposed to be
delivered by the end of January.

Citing production problems and export restrictions,
AstraZeneca in March said it would deliver to the EU only 100
million doses by the end of June. It delivered 30 million in
total by the end of March.

The vaccine was approved for use in the EU in late January,
but the EU Commission has said AstraZeneca should have applied
earlier.
(Reporting by Francesco Guarascio; Editing by Bill Berkrot)

More News
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.